^
Association details:
| Biomarker: | ARID1A deletion |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | fulvestrant (Selective estrogen receptor degrader) |
| Direction: | Resistant |
Evidence:
Source:
Title:
NG05 - Epigenetic mechanisms of endocrine therapy response in breast cancer
Published date:
03/10/2021
Excerpt:
ARID1A as the top candidate whose loss determined resistance to the ER degrader in the clinic fulvestrant...FOXA1 and ARID1A mutations are associated with worse outcome to endocrine therapy and position these genetic alterations as potential biomarkers of endocrine therapy response for the treatment of metastatic ER+ breast cancer.
